Literature DB >> 26155424

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Arianna Calcinotto1, Maurilio Ponzoni2, Roberto Ria3, Matteo Grioni4, Elena Cattaneo4, Isabella Villa5, Maria Teresa Sabrina Bertilaccio6, Marta Chesi7, Alessandro Rubinacci5, Giovanni Tonon6, P Leif Bergsagel7, Angelo Vacca3, Matteo Bellone4.   

Abstract

While multiple myeloma (MM) is almost invariably preceded by asymptomatic monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering MM (SMM), the alterations of the bone marrow (BM) microenvironment that establish progression to symptomatic disease are circumstantial. Here we show that in Vk*MYC mice harboring oncogene-driven plasma cell proliferative disorder, disease appearance associated with substantial modifications of the BM microenvironment, including a progressive accumulation of both CD8+ and CD4+ T cells with a dominant T helper type 1 (Th1) response. Progression from asymptomatic to symptomatic MM was characterized by further BM accrual of T cells with reduced Th1 and persistently increased Th2 cytokine production, which associated with accumulation of CD206+Tie2+ macrophages, and increased pro-angiogenic cytokines and microvessel density (MVD). Notably, MVD was also increased at diagnosis in the BM of MGUS and SMM patients that subsequently progressed to MM when compared with MGUS and SMM that remained quiescent. These findings suggest a multistep pathogenic process in MM, in which the immune system may contribute to angiogenesis and disease progression. They also suggest initiating a large multicenter study to investigate MVD in asymptomatic patients as prognostic factor for the progression and outcome of this disease.

Entities:  

Keywords:  BM, bone marrow; BMb, BM biopsies; M-spike, monoclonal (M) protein; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MVD, microvessel density; SMM, smoldering multiple myeloma; T cells; TAMs, M2 tumor associated macrophages; TEMs, Tie2-expressing macrophages; angiogenesis; macrophages; multiple myeloma; smoldering multiple myeloma

Year:  2015        PMID: 26155424      PMCID: PMC4485787          DOI: 10.1080/2162402X.2015.1008850

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  49 in total

Review 1.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

Review 2.  Pathogenesis of myeloma.

Authors:  Kenneth C Anderson; Ruben D Carrasco
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

3.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

4.  Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.

Authors:  M G Alexandrakis; F H Passam; K Sfiridaki; J Moschandrea; C Pappa; D Liapi; E Petreli; P Roussou; D S Kyriakou
Journal:  Leuk Res       Date:  2004-03       Impact factor: 3.156

Review 5.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

Authors:  Michele De Palma; Craig Murdoch; Mary Anna Venneri; Luigi Naldini; Claire E Lewis
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

6.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

7.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

8.  Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Authors:  Donna Weber; Kim Rankin; Maria Gavino; Kay Delasalle; Raymond Alexanian
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

9.  Multiple myeloma macrophages: pivotal players in the tumor microenvironment.

Authors:  Simona Berardi; Roberto Ria; Antonia Reale; Annunziata De Luisi; Ivana Catacchio; Michele Moschetta; Angelo Vacca
Journal:  J Oncol       Date:  2013-01-30       Impact factor: 4.375

10.  Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Maurizio Affer; Marta Chesi; Wei-Dong G Chen; Jonathan J Keats; Yulia N Demchenko; Anna V Roschke; Scott Van Wier; Rafael Fonseca
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

View more
  13 in total

1.  Clinicopathological significance of NGX6 expression in breast cancer and its relationship to angiogenesis.

Authors:  Jidong Xiao; Yuyao Mao; Yuanquan Zhou; Kaimin Xiang
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 2.  Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer.

Authors:  Matteo Bellone; Arianna Brevi; Samuel Huber
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

Review 3.  Macrophages in multiple myeloma: key roles and therapeutic strategies.

Authors:  Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

4.  Targeting vasculogenesis to prevent progression in multiple myeloma.

Authors:  M Moschetta; Y Mishima; Y Kawano; S Manier; B Paiva; L Palomera; Y Aljawai; A Calcinotto; C Unitt; I Sahin; A Sacco; S Glavey; J Shi; M R Reagan; F Prosper; M Bellone; M Chesi; L P Bergsagel; A Vacca; A M Roccaro; I M Ghobrial
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

Review 5.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

6.  Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Authors:  Rachel E Cooke; Nicholas A Gherardin; Simon J Harrison; Hang Quach; Dale I Godfrey; Miles Prince; Rachel Koldej; David S Ritchie
Journal:  J Transl Med       Date:  2016-09-06       Impact factor: 5.531

7.  A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

Authors:  C Botta; M T Di Martino; D Ciliberto; M Cucè; P Correale; M Rossi; P Tagliaferri; P Tassone
Journal:  Blood Cancer J       Date:  2016-12-16       Impact factor: 11.037

Review 8.  Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.

Authors:  Barbara Castella; Assunta Melaccio; Myriam Foglietta; Chiara Riganti; Massimo Massaia
Journal:  Front Oncol       Date:  2018-11-06       Impact factor: 6.244

9.  Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

Authors:  Arianna Calcinotto; Arianna Brevi; Marta Chesi; Roberto Ferrarese; Laura Garcia Perez; Matteo Grioni; Shaji Kumar; Victoria M Garbitt; Meaghen E Sharik; Kimberly J Henderson; Giovanni Tonon; Michio Tomura; Yoshihiro Miwa; Enric Esplugues; Richard A Flavell; Samuel Huber; Filippo Canducci; Vincent S Rajkumar; P Leif Bergsagel; Matteo Bellone
Journal:  Nat Commun       Date:  2018-12-03       Impact factor: 14.919

10.  Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.

Authors:  Marta Chesi; Caleb K Stein; Victoria M Garbitt; Meaghen E Sharik; Yan W Asmann; Matteo Bergsagel; Daniel L Riggs; Seth J Welsh; Erin W Meermeier; Shaji K Kumar; Esteban Braggio; P Leif Bergsagel
Journal:  Blood Cancer Discov       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.